linjc16/ctgov huggingface dataset:
DNA CDO1 and CELF4 Methylation for Endometrial Cancer Screening

Study Overview
=================
Brief Summary
-----------------
Based on the previous study of NCT04651738, we performed this trial to further confirm the accuracy of host DNA CDO1 and CELF4 methylation for endometrial cancer screening. This study would provide profound basis for the approval of assay kit of DNA methylation in China for endometrial screening. Four hospitals, including Peking Union Medical College Hospital, would enroll eligible patients in this study. The cervical cytology of 3 ml will be collected for the detection of DNA CDO1 and CELF4 methylation, and the results will compared with the endometrial histological pathology, which is achieved after collection of cervical cytology, by surgeries including hysteroscopy, dilation and curettage, total hysterectomy and others. The methylation testing would be double-blinded in operators and analysts. The study will enroll at least 7150 patients.

Official Title
-----------------
The Accuracy of Host DNA CDO1 and CELF4 Methylation for Endometrial Cancer Screening: a Multi-center, Double-blind, Parallel Controlled Clinical Trials

Conditions
-----------------
Endometrial Cancer, Cancer Screening, DNA Methylation, Testing Accuracy, Cervical Cytology

Intervention / Treatment
-----------------
* Diagnostic Test: DNA methylation testing


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: With uerine and uterine cervix intact Aged 18 years or older With accessible histological results of endometrium Signed an approved informed consents With accessible cervical cytology before harvesting endometrial histology Exclusion Criteria: Not meeting all of the inclusion criteria

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: DNA methylation testing|The cervical cytology of 3 ml will be collected for the detection of DNA CDO1 and CELF4 methylation.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Sensitivity of methylation testing | Sensitivity of methylation testing of cervical cytology compared with histology | One week | 
| Specificity of methylation testing | Specificity of methylation testing of cervical cytology compared with histology | One week | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Positive predictive value of methylation testing | Positive predictive value of methylation testing of cervical cytology compared with histology | One week | 
| Negative predictive value of methylation testing | Negative predictive value of methylation testing of cervical cytology compared with histology | One week |
Treatment of Patients With Major Depressive Disorder With MK0869 (0869-073)

Study Overview
=================
Brief Summary
-----------------
A clinical study to determine the efficacy and safety of MK0869 in the treatment of depression.

Detailed Description
-----------------
The duration of treatment is 8 weeks.

Official Title
-----------------
A Double-Blind, Multicenter, Placebo-Controlled Study of MK0869 in the Treatment of Patients With Major Depressive Disorder

Conditions
-----------------
Major Depressive Disorder

Intervention / Treatment
-----------------
* Drug: MK0869, aprepitant
* Drug: Comparator: placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Patients with Major Depressive Disorder

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: MK0869, aprepitant|nan|
|Drug: Comparator: placebo|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| HAMD-17 total score; Tolerability |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| CGI-I Scale score; Sheehan Disability Scale |  |  |
Optic Nerve Sheath Diameter for Prediction of Outcome After Cardiac Arrest

Study Overview
=================
Brief Summary
-----------------
Early prognostication in resuscitated cardiac arrest (CA) patients, within the first day after admission in the intensive care unit (ICU), remains difficult. Optic nerve sheath diameter (ONSD) measurement could predict increased intracranial pressure. Preliminary works showed that ONSD measurement could be used to predict outcome in post-CA patients. The aim of this study was to assess the ability of bedside ONSD ultrasonographic measurement to predict survival and Cerebral Performance Category (CPC) score at hospital discharge in post-cardiac arrest patients treated with therapeutic hypothermia (TH).

Detailed Description
-----------------
Prospective observational study including all consecutive successfully resuscitated and TH-treated CA patients without traumatic or neurological etiology of CA in two French ICUs. ONSD measurements were performed on day 1, 2, and 3 after return of spontaneous circulation (ONSD1,2,3 respectively). The primary outcome is survival at hospital discharge (with an average follow-up of 3 month until ICU admission).

Official Title
-----------------
The Optic Nerve Sheath Diameter for Prediction of Outcome After Cardiac Arrest: a Pilot Prospective Study

Conditions
-----------------
Cardiac Arrest

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Unconscious (Glasgow Coma Scale ≤6) ≥18 years old Admitted in ICU after successful resuscitation from CA Treated with TH targeted to 33°C Exclusion Criteria: unavailable ONSD measurement within 24 hours after return of spontaneous circulation (unavailable investigator, early death, or major hemodynamic instability) Traumatic or neurological origin of CA Previous cerebrovascular disease Facial trauma affecting the orbits and/or eyeballs Previous history of ocular pathology such as exophthalmia, glaucoma or cataract.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| In-hospital mortality | participants will be followed for the duration of hospital stay, an expected average of 3 months. | 3 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cardiac arrest, neuroprognostication, optic nerve sheath diameter, outcome, ultrasonography
A Pilot Evaluation of Adhesives and How They Are Impacted by Output

Study Overview
=================
Brief Summary
-----------------
The study investigates the impact real output has on the adhesion of adhesives.

Official Title
-----------------
A Pilot Evaluation of Adhesives and How They Are Impacted by Output

Conditions
-----------------
Ileostomy

Intervention / Treatment
-----------------
* Other: adhesive strip


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Have given written informed consent Be at least 18 years of age and have full legal capacity Have had an ileostomy for more than one year Have intact skin on the area used in the evaluation Has an ileostomy with a diameter up to (≤) 35 mm Have a peristomal area accessible for application of patches/adhesive strips (assessed by investigating scientist) Exclusion Criteria: Currently receiving or have within the past 2 month received radio- and/or chemotherapy Currently receiving or have within the past month received topical steroid treatment in the peristomal skin area or systemic steroid (tablet/injection) treatment. Are pregnant or breastfeeding Having dermatological problems in the peristomal- or abdominal area (assessed by investigating scientist) Participating in other interventional clinical investigations or have previously participated in this evaluation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Cohort 1b<br>The subject test one adhesive strip on the peristomal area | Other: adhesive strip<br>* Adhesive strip with a standard adhesive base<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Remaining adhesive area of adhesive | The remaining adherent area of the adhesive is assessed by subtracting the area of output and swelling from the total adhesive area | 30 hours |
Influence of Stretching on Muscle Performance

Study Overview
=================
Brief Summary
-----------------
The stretching is performed within sports to improve muscle performance and prevent muscle injury. However, recent studies are contradictory with common practice. Then raised the possibility that stretching before physical activity performed can decrease the muscle performance of healthy subjects.

Official Title
-----------------
Influence of Stretching Hamstring and Quadriceps Femoral Muscles on Peak Torque and the Maximum Power of the Knee

Conditions
-----------------
Muscle Strength

Intervention / Treatment
-----------------
* Other: Stretching


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Between 18 and 30 years. History of at least 3 months without performing any physical activity Exclusion Criteria: Recent history of injuries in lower limbs. Contraindication to agree with the Par-Q form. Make physical activity during the search Fails every session of stretching BMI above 28 Pain in the lumbar spine I had muscle shortening in Test Thomas (TT) and / or test the popliteal angle (TAP)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 30 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Masking: Single


Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Stretching|Participants were divided into 3 groups. The group was referred to stretching 3 weekly for 4 consecutive weeks. Group B went 4 weeks without any intervention and held only one stretch before the re-test. And the group C performed passive knee mobilization. All participants were assessed for goniometry of the knee in flexion and extension and peak torque and power on the isokinetic dynamometer.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Muscle Strength, Torque, Muscle Stretching Exercises, Range of Motion
A Phase III Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Compared With Latanoprost Ophthalmic Solution in Subjects With OAG or OHT

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to investigate the intraocular pressure-lowering effect and the safety of DE-117 ophthalmic solution compared with Latanoprost ophthalmic solution in subjects with open angle glaucoma or ocular hypertension.

Official Title
-----------------
A Phase III, Randomized, Observer-Masked, Active-Controlled, Parallel-Group, Multinational and Multicenter Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution 0.002% Compared With Latanoprost Ophthalmic Solution 0.005% in Subjects With Open-Angle Glaucoma or Ocular Hypertension- PEONY Study

Conditions
-----------------
Open Angle Glaucoma or Ocular Hypertension

Intervention / Treatment
-----------------
* Drug: DE-117
* Drug: Latanoprost ophthalmic solution


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with open angle glaucoma or ocular hypertension in both eyes Exclusion Criteria: Patients at risk of progression of visual field loss Patients with severe visual field defect Patients with any diseases that preclude participation in this study for safety reasons

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: DE-117 ophthalmic solution<br> | Drug: DE-117<br>* DE-117 ophthalmic solution will be taken one drop, once daily for 3 months in both eyes.<br>|
| Active Comparator: Latanoprost ophthalmic solution 0.005%<br> | Drug: Latanoprost ophthalmic solution<br>* Latanoprost ophthalmic solution will be taken one drop, once daily for 3 months in both eyes.<br>* Other names: Xalatan;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mean diurnal intraocular pressure |  | Month 3 |
International Extranodal NK/T-cell Lymphoma Project

Study Overview
=================
Brief Summary
-----------------
This study is to explore risk factors for poor progression-free survival (PFS) and overall survival (OS) in ENKTL, and establish a prognostic model for ENKTL patients treated with non-anthracycline based treatment.

Detailed Description
-----------------
This is a retrospective cohort study using anonymized information from patients with ENKTL. The following criteria are required: (1) Patients diagnosed with ENKTL, nasal type between January 1, 1995 and December 31, 2014; (2) Patients treated with non-anthracycline based therapy as an initial treatment. The pathology of initial diagnosis was reviewed by designated pathologists.

Official Title
-----------------
International Extranodal NK/T-cell Lymphoma Project: Prognostic Factors in the Era of Nonanthracycline-based Treatment

Conditions
-----------------
Extranodal NK/T-cell Lymphoma, Nasal Type

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients diagnosed with ENKTL, nasal type Patients diagnosed between January 1, 1995 and December 31, 2014 Patients treated with nonanthracycline-based therapy as the initial treatment after diagnosis Nonanthracycline-based therapy includes the following treatments: Radiotherapy including concurrent chemoradiation Chemotherapy not including anthracycline such as doxorubicin (e.g. SMILE, VIPD) The type of salvage treatment will not be a criterion for exclusion. Thus, patients who had received various kinds of salvage treatment including anthracycline-containing regimens can be included. Patients who had undergone autologous or allogeneic stem cell transplantation can also be included in the analysis if they satisfy the above-mentioned inclusion criteria. Exclusion Criteria: Patients who had received anthracycline-based therapy, such as CHOP or CHOP-like regimens, as the initial treatment. Patients who do not have pathology slides available for central review.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Training cohort<br>Patients diagnosed with ENKTL, nasal type between January 1, 1995 and December 31, 2013; Patients treated with non-anthracycline based therapy as an initial treatment. | |
| Validation cohort<br>Patients diagnosed with ENKTL, nasal type between January 1, 1998 and December 31, 2014; Patients treated with non-anthracycline based therapy as an initial treatment. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall survival | Time between the date of diagnosis and any kinds of death | 5 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Progression-free survival | Time between the date of diagnosis and any kinds of death or relapse/progression | 5 year |
PECARN Emergency Care Registry

Study Overview
=================
Brief Summary
-----------------
The objectives of this study are to: develop an emergency care visit registry for pediatric patients for Quality Improvement purposes and to support future research; to use the emergency care visit registry to collect stakeholder-prioritized emergency care performance improvement measures for important pediatric medical and trauma conditions; and report emergency care performance improvement measures.

Official Title
-----------------
Improving the Quality of Pediatric Emergency Care Using an Electronic Medical Record Registry and Clinician Feedback

Conditions
-----------------
Pediatric Emergency Care

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients (0-18) who registered in the ED Exclusion Criteria: Greater than 18 years of age for ED patients

Ages Eligible for Study
-----------------
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| ED Patients<br>All patients (age 0-18 regardless of race, ethnicity, or gender and of diagnosis or chronic health condition) who are registered in the ED. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The Number of Visits Obtained From Electronic Health Record Data From the Sites | The number of visits obtained from electronic health record data from the sites | January 2012 - June 2016 |
Botulinum Toxin Injection for Preventing Secondary Atrial Fibrillation in Patient With Supra-ventricular Tachyarrythmias

Study Overview
=================
Brief Summary
-----------------
The investigators have conducted a prospective, double-blind, randomized study to assess the comparative safety and efficacy of two different ablation strategies, RFA versus RFA plus botulinum toxin injection, in patients with supra-ventricular tachyarrhythmias. Results were assessed with the use of an implanted monitoring device (IMD).

Conditions
-----------------
Supra-ventricular Tachyarrhythmias

Intervention / Treatment
-----------------
* Procedure: radiofrequency ablation
* Drug: botulinum toxin injection


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: atrial flutter, AV nodal re-entry tachycardia, focal atrial tachycardia, WPW syndrome secondary atrial fibrillation Exclusion Criteria: congestive heart failure LV ejection fraction < 35% left atrial diameter > 60 mm

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: RFA<br>Mapping and radiofrequency ablation are performed by using standard methods. | Procedure: radiofrequency ablation<br> <br> |
| Active Comparator: RFA+BT injection<br>Mapping and radiofrequency ablation are performed by using standard methods. Injection of the botulinum toxin is performed in main anatomical zones of ganglionated plexuses of left atrium using Myostar catheter (Biosense Webster). | Procedure: radiofrequency ablation<br> <br> Drug: botulinum toxin injection<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| number of episodes of atrial fibrillation |  | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| serious adverse events |  | 1 year |
Sedation for Upper Gastrointestinal Endoscopy in Pediatric Patients

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to compere between Propofol-Ketamine combination and Dexmedetomidine-Ketamine combination for sedation in upper gastrointestinal endoscopy in paediatric patients.

Official Title
-----------------
Comparative Study Between Propofol-Ketamine Combination and Dexmedetomidine-Ketamine Combination for Sedation in Upper Gastrointestinal Endoscopy in Paediatric Patients.

Conditions
-----------------
Upper Gastrointestinal Endoscopy

Intervention / Treatment
-----------------
* Drug: Dexmedetomidine-ketamine
* Drug: propofol-ketamine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: American Society of Anesthesiologists ASA I-II patients aging 2-7 years. Exclusion Criteria: known allergy to any of the study drugs, significant cardiovascular disease vomiting.

Ages Eligible for Study
-----------------
Minimum Age: 2 Years
Maximum Age: 7 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Group PK<br>Propofol-Ketamine group: patients in this group will receive IV ketamine at a dose of 1mg.kg-1 in addition to IV propofol 1mg.kg-1 for induction with added doses of propofol 1mg.kg-1 when needed. | Drug: propofol-ketamine<br> <br> |
| Experimental: Group DK<br>Dexmedetomidine-Ketamine group: patients in this group will receive IV ketamine at a dose of 1mg.kg-1 in addition to IV dexmedetomidine 0.5 mcg.kg-1 for induction with additional doses of dexmedetomidine 0.5mcg.kg-1 when required | Drug: Dexmedetomidine-ketamine<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| length of stay in PACU |  | three months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Sedation, Pediatric Patients